The expansion comprises a new 30,000 sqft production unit that doubles capacity at the mid Wales plant, which is at the heart of what the contract manufacturing organisation (CMO) described as a “nascent pharmaceutical cluster.”
Bilcare managing director Mohan Bhandari explained that: “The need to clinically test drug efficacy and safety in diverse population groups across multiple geographic regions is becoming a crucial necessity.
“This necessity has lead Bilcare to expand and open new facilities in US, Europe and Asia. With this expansion of the second centre at Crickhowell, we are now geared to cater to ever challenging requirements of our global customers.”